Chipotle stock falls as Salmonella outbreak toll hits 345 across 27 states
Chipotle Mexican Grill Inc. faces mounting pressure as the FDA confirms 345 Salmonella illnesses linked to jalapeños from Sinaloa, Mexico. Despite removing the product and switching suppliers, the stock declined due to legal uncertainties and weak technical indicators, trading below key moving averages.

*this image is generated using AI for illustrative purposes only.
Chipotle Mexican Grill Inc. (NYSE: CMG) shares declined 0.70% to $31.91 on Tuesday as the scope of a multistate Salmonella outbreak expanded significantly. The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) confirmed that 345 people across 27 states have been sickened, with 36 hospitalizations reported. The outbreak is linked to fresh jalapeños imported from Sinaloa, Mexico, by Coast Citrus Distributors. Chipotle began switching suppliers at affected locations on July 20 and has ceased serving the implicated product. Despite the removal of the ingredient, the rising case count intensifies scrutiny over the company’s supply chain transparency and potential liability exposure.
The legal landscape remains volatile following the filing of the first personal injury lawsuit on August 5, 2026, by Minnesota resident Kristen Behne in federal court (Case No. 26-cv-03514). The complaint alleges she contracted a blood infection from a burrito bowl. Securities law firm Schall, Brown & Schwartz LLP (SBS) has launched an investigation into potential disclosure failures. Ryan Osterholm of OFT Law criticized Chipotle for not disclosing the specific supplier or full extent of impacted stores earlier. While Minnesota health officials stated there are no ongoing concerns, the FDA’s investigation continues, with 177 of 191 interviewed patients reporting they ate at Mexican-style restaurants, including Chipotle and QDOBA.
Operational and Supply Chain Response
Chipotle identified jalapeños as the contamination source and proactively removed them from affected locations. The company sourced these peppers from Coast Citrus Distributors, which imported them from Sinaloa, Mexico. By switching suppliers on July 20, Chipotle aims to mitigate further health risks. The FDA stated it does not consider there to be a current ongoing risk to consumers at Chipotle or QDOBA after the restaurants removed the affected products. However, the operational disruption highlights vulnerabilities in local supply chains, potentially increasing short-term overhead costs as the company secures alternative growers.
| Metric | Value |
|---|---|
| Total Sickened | 345 |
| States Affected | 27 |
| Hospitalizations | 36 |
| Deaths Reported | 0 |
| Primary Source | Jalapeños from Sinaloa |
Market Reaction and Technical Outlook
Chipotle’s stock performance reflects broader investor anxiety. Shares are down 23.25% over the past 12 months. Technically, the stock trades below key moving averages: 7.8% below its 200-day simple moving average (SMA) of $34.65, 5.9% below the 20-day SMA of $33.94, and 3.1% below the 50-day SMA of $32.97. Although the 20-day SMA remains above the 50-day SMA, offering a slight short-term signal, momentum is weak. The Moving Average Convergence Divergence (MACD) indicator is below its signal line with a negative histogram, suggesting the recent rebound is losing steam. Key resistance sits near $33.50, while support is around $31.
What the Numbers Show
The divergence between the FDA’s declaration of no ongoing risk and the continued decline in stock price underscores the market’s sensitivity to litigation risk rather than immediate operational failure. With 345 confirmed cases and 36 hospitalizations, the potential for class-action lawsuits or significant regulatory fines poses a material tail risk. The fact that 93% of interviewed patients ate at Mexican-style restaurants reinforces the sector-wide reputational damage, even as Chipotle isolates the issue to a single supplier. Investors are pricing in not just the cost of pulled ingredients, but the long-term brand erosion associated with food safety lapses.
How might the outcome of the initial personal injury lawsuit filed by Kristen Behne influence the likelihood and scale of subsequent class-action litigation against Chipotle?
Will Chipotle implement stricter third-party auditing protocols for its Mexican suppliers to prevent future contamination events, and what impact could this have on its cost structure?
Could the FDA’s ongoing investigation lead to broader regulatory changes regarding food safety disclosures for fast-casual restaurant chains?

































